These innovative agents represent a significant advancement in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose https://arranlbvi097983.blogsidea.com/45809440/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide